Company Status: Amalgamated As on: 06-Aug-2019
D&B Reports |
|---|
|
Basic Report
INR 6000.00 /-
|
|
Quick Check Report
INR 2500.00 /-
|
|
Compliance Report
INR 14000.00 /-
|
|
Sectoral Risk Outlook (Industry Report)
Sectoral Risk Outlook (Industry Report) Status : Unavailable
Financial Year : NA
|
Global Inhalation And Nasal Spray Generic Drugs Market Growth Outlook 2015-2027 By- Ranbaxy Laboratories Ltd., Novartis AG (Sandoz International GmbH), Cipla Ltd., Nephron Pharmaceuticals Corporation, Allergan plc - SoccerNurds
Global Imipenem and Cilastatin Sodium Market 2025 by Trends, Strategies and Growth by leading Manufacturers High Science Co.,Ltd., Shenzhen Haibin Pharmaceutical, Savior Lifetec Corporation, Ranbaxy Laboratories, Ranbaxy Laboratories Ltd - The Bisouv Network
Global Alopecia Treatment (Hair Loss) Market 2021: Global Industry Expand with Significant CAGR by 2028|| Top Competitors- Cipla,Viviscal,Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd - South Florida Theater Review
Global Enalapril Market 2021 Recovering From Covid-19 Outbreak | Know About Brand Players: Apotex Inc, Sandoz Inc, Krka Dd Novo Mesto, Apothecon Inc Div Bristol Myers Squibb, Ranbaxy Laboratories Ltd, etc. | InForGrowth - NeighborWebSJ
Hair Loss and Growth Treatments and Products Market (COVID-19) to Witness Astonishing Growth by Forecast 2021-2027 |Cipla, Viviscal, Regaine, Merck & Co., Inc, etc - NeighborWebSJ
Global Alopecia Market for robust expansion throughout the forecast period 2020-2026 – NeighborWebSJ - NeighborWebSJ
Global API Contract Manufacturing Market Focuses on SWOT analysis, Industry Synopsis, Development Plans 2021 to 2026 – NeighborWebSJ - NeighborWebSJ
Erythropoietin Stimulating Agents Market Future Scenario, Growth rate, Market Segmentation, and Industrial Opportunities to 2027 – The Bisouv Network - The Bisouv Network
Global Alopecia Treatment (Hair Loss) Market Set To Boom With Top Booming Companies-Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd,Phyto – Alès Groupe - The Courier
Barotrauma Market Advancing the Growth Globally: Market Dynamics, Trends, Efficiencies Forecast 2026 - NeighborWebSJ
Inhalation And Nasal Spray Generic Drugs Market: Industry Analysis And Forecast 2026 – The Bisouv Network - The Bisouv Network
Hair Loss Treatment Products Market Size 2021 | Global Industry Share, Trends, Growth Insights, SWOT Analysis by Top Key Vendors and Forecast to 2027 - The Bisouv Network
Global Enalapril Industry Research Report, Growth Trends and Competitive Analysis 2021-2027| Apotex Inc, Apothecon Inc Div Bristol Myers Squibb, Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa - SoccerNurds
Controversy swirls around India’s homegrown Covid vaccine - Mint
Androgenetic Alopecia Treatment Market will Explore Robust Size & Growth During 2018-2026 – NY Market Reports - NY Market Reports
Generic Drugs Market 2020-2026 By Application, By Product Type, Top Key Players: Ranbaxy Laboratories, Ltd, Actavis, Mylan Inc., Teva Pharmaceutical Industries, Ltd., Dr. Reddy’s Laboratories - The Courier
API Contract Manufacturing Market Size 2021 | Global Industry Analysis, Development, Scope, Trends, Forecast to 2027 – Express Keeper - Express Keeper
Botanical and Plant-Derived Drugs Market 2021 Focusing on Top Key Players like Abbott Laboratories, Eli Lilly, Medigene, Pfizer, Lupin Ltd., Johnson & Johnson, Ranbaxy Laboratories Ltd., Novartis International AG, Glaxosmithkline and Leo Pharma - The Courier
India's Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats - Reuters
U.S. class action asserts India's Ranbaxy manipulated FDA rules - Reuters
Ranbaxy shares to stop trading on exchanges from 6 April - Livemint
Sun Pharma buys Ranbaxy to create generics giant - Livemint
Singapore court rejects Singh brothers' plea against arbitral award in Daiichi case - VCCircle
Ranbaxy Laboratories posts Rs160 crore loss in Dec quarter - Livemint
Global Alopecia Treatment (Hair Loss) Market Regional Overview, Leading Company Analysis And Forecast To 2026 | Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd,Phyto – Alès Groupe - The Courier
Ex-Ranbaxy owners told to pay Rs2,500 crore for hiding facts in Daiichi sale - Livemint
Six business lessons from the Daiichi–Ranbaxy deal fiasco - Livemint
Ranbaxy pleads guilty, to pay $500 million in U.S. settlement - Reuters
Ranbaxy And The Culture Of Jugaad: What Brought A Leading Company Down - Outlook India
Ranbaxy agrees to $4 billion buyout - Jacksonville Daily Record
Ranbaxy agrees to $4 billion buyout Jacksonville Daily Record
Ranbaxy to contest US pharma company to protect drug patent - Hindu Business Line
Ranbaxy to contest US pharma company to protect drug patent Hindu Business Line
Making Ranbaxy units cGMP compliant time consuming: Sun Pharma - Livemint
Ranbaxy recalls some batches of generic Lipitor in latest quality blow - Reuters
Ranbaxy scrambles for ingredients to make generic Nexium - Reuters
Sun Pharma sells Ranbaxy divisions to Strides Arcolab for Rs165 crore - Livemint
Daiichi-Ranbaxy row: Delhi HC restrains Singh brothers from using bank a/cs - Livemint
FDA may inspect one Ranbaxy plant in fiscal 2017: Dilip Shanghvi - Livemint
Sun Pharma Took Two Years To Integrate Ranbaxy’s Employees - BW Businessworld
Sun Pharma Took Two Years To Integrate Ranbaxy’s Employees BW Businessworld
FDA Says Ranbaxy Can’t Make Generic Versions of Nexium, Valcyte - Wall Street Journal
FDA Says Ranbaxy Can’t Make Generic Versions of Nexium, Valcyte Wall Street Journal
Daiichi-Ranbaxy row: HC allows the sale of Singh brothers firms to repay the Rs 3,500 crore arbitration... - Medical Dialogues
Ranbaxy Laboratories posts surprise March-quarter loss on write-offs - indiatvnews.com
Sun Pharma’s Mohali unit violated manufacturing norms, finds US FDA - Livemint
Religare group emerges out of Ranbaxy shadow - Livemint
Ranbaxy gets FDA approval for Novartis's Diovan generic - Reuters India
Ranbaxy gets FDA approval for Novartis's Diovan generic Reuters India
Ranbaxy fallout: Indian pharma under the microscope - Livemint
Sun Pharma shares soar as Ranbaxy to delist - Livemint
Ranbaxy in licensing pact with Gilead Sciences for HIV drug - Hindu Business Line
Ranbaxy in licensing pact with Gilead Sciences for HIV drug Hindu Business Line
Truth behind FDA ban on Ranbaxy found: Human hair embedded in tablet - Firstpost
The rise and fall of Singh brothers' business empire - CNBCTV18
Sun Pharma warns on revenue, profit over Ranbaxy takeover - Livemint
FDA bans imports from Sun Pharma plant in India crackdown - Reuters
Sun Pharma, Ranbaxy shares decline after court stalls merger - Livemint
The CEO who capped a $37 billion recovery with a cancer drug deal - Livemint
Ranbaxy shares crash as Mohali plant comes under FDA scanner - Livemint
Competition Commission extends Sun Pharma-Ranbaxy probe to new stage - Livemint
Ranbaxy and Teva settle with NY Attorney General over collusion - Reuters
Sun Pharma hikes stake in Zenotech to 57.56% - VCCircle
Sun Pharmaceutical withdraws suit filed by Ranbaxy against USFDA - Business Today
Culture of 'Bending Rules' in India Challenges U.S. Drug Agency - Bloomberg
All’s Not Well In Sun Pharma-Ranbaxy Human Resource Integration? - BloombergQuint
Ranbaxy Wins Approval for Generic Blood-Pressure Drug Diovan - Wall Street Journal
Ranbaxy Wins Approval for Generic Blood-Pressure Drug Diovan Wall Street Journal
SC gives Andhra Pradesh HC two days to decide Sun-Ranbaxy issue - Livemint
Petition against Sun Pharma for allegedly violating merger norms - Livemint
Singh brothers, ex-promoters of Ranbaxy held in Rs 740 crore fraud | What the case is all about - Jagran English
FDA bans Ranbaxy’s fourth plant in India - The Hindu
FDA bans Ranbaxy’s fourth plant in India The Hindu
Ranbaxy resumes supply of Atorvastatin tablets in US market - The Hindu
Sun Pharma-Ranbaxy Laboratories deal comes under CCI scanner - indiatvnews.com
Sun Pharma-Ranbaxy Laboratories deal comes under CCI scanner indiatvnews.com
Sun Pharma denies wrongdoing, says some issues are factually incorrect - Livemint
Pfizer, Ranbaxy win lawsuit over generic Lipitor - Deccan Herald
Pfizer, Ranbaxy win lawsuit over generic Lipitor Deccan Herald
High Court approves merger of Sun Pharma, Ranbaxy - Equity Bulls
High Court approves merger of Sun Pharma, Ranbaxy Equity Bulls
Ranbaxy posts profit in July-Sept quarter - MarketWatch
Ranbaxy posts profit in July-Sept quarter MarketWatch
CCI clears Sun-Ranbaxy deal with some riders - Livemint
Domestic M&As surge to a four-year high in 2014 - Livemint
Fortis shareholders vote out former Ranbaxy CEO Brian Tempest as director - VCCircle
Sun Pharma-Ranbaxy merger: Honeymoon over, now to make it work - Livemint
Ranbaxy Laboratories dips nearly 7% on bourses - Livemint
Ranbaxy’s performance hinges on generic Diovan - Livemint
Ranbaxy accused of gaming FDA rules to thwart rival drug makers - Livemint
Daiichi Sankyo sells entire 8.9% stake in Sun Pharma for $3.18B; Temasek, GIC among buyers - VC Circle
Sun Pharma asked to pay Rs 279 crore GST dues on Ranbaxy arbitration - CNBCTV18
Sobti quits Ranbaxy over differences with management - The Hindu
How Singh brothers got into trouble - bit by bit - Business Today
How Singh brothers got into trouble - bit by bit Business Today
Singh brothers sent to 14 days judicial custody in Religare case - Livemint
Open offer for Zenotech fails to meet target - Livemint
Sun Pharma-Ranbaxy merger gets BSE, NSE clearance - Livemint
Fortis tries to leave its past behind by seeking to rebrand as Parkway - VCCircle
‘Bottle of Lies’: Book on Generic Drugs ‘Exposes’ Indian Companies - The Quint
Delhi HC allows Daiichi Sankyo to recover Rs3,500 crore from Singh brothers - Livemint
Know 5 things before buying Sun Pharma shares - Economic Times
Know 5 things before buying Sun Pharma shares Economic Times
Andhra HC lifts stay on Sun Pharma-Ranbaxy merger - VC Circle
Ranbaxy case: SC rejects plea by Singh brothers against Daiichi Sankyo’s Rs3,500 crore award - Livemint
FDA bans imports from canadian drugmaker Apotex’s India plant - Livemint
Class Certification Denied in Suit Over Adulterated Ranbaxy Drugs | New Jersey Law Journal - Law.com
Ranbaxy halts drug ingredients shipment from Toansa, Dewas plants - Livemint
Ranbaxy keeps sales forecast as India reviews US court ruling - Livemint
CIN.
L24231PB1961PLC003747
ROC Code
RoC-Chandigarh
Date of Incorporation
16/06/1961
D&B D-U-N-S® Number
65-XXX-4795
Company Category
Company limited by Shares
Company SubCategory
Non-govt company
Class of Company
Public
Industry
MANUFACTURING
Authorised Capital( INR)
3,000,000,000
Paid up Capital( INR)
2,128,317,485
Number of Members
0
Registered Address
A-41 Industrial Area Phase VIII-A SAS Nagar PB 160071 IN
Email Id
secretarial@ranbaxy.com
Whether Listed or not
Listed
Last AGM
28/07/2014
Last Balance Sheet
31/03/2014
Registration Number
3747
| Charge Holder Name | Assets under charge | Charge Amount | Date of Creation | Date of Modification | Status |
|---|
| Identification Number | Principal Names | Designation | Begin date | End date |
|---|---|---|---|---|
| 00021752 | RAJESH VIREN SHAH | Director | 19/12/2008 | 13/10/2020 |
| 01929668 | ARUN SAWHNEY | Managing Director | 09/05/2011 | 02/10/2020 |
| 02143003 | PERCY KEKU SHROFF | Director | 27/03/2009 | 22/07/2021 |
| 02436813 | TAKASHI SHODA | Director | 19/12/2008 | - |
| 02439360 | AKIHIRO WATANABE | Director | 19/12/2008 | 05/10/2020 |
| 02439401 | TSUTOMU UNE | Director | 19/12/2008 | 13/10/2020 |
| 02454431 | ANTHONY HUGH WILD | Director | 19/12/2008 | - |
| 03562763 | KAZUNORI HIROKAWA | Director | 09/05/2012 | 27/06/2012 |
| XXXXXXXXXX | SUSHIL KUMAR PATAWARI | Company Secretary | 21/09/1995 | 09/12/2016 |
